90 Bridge Street
About Siamab TherapeuticsSiamab Therapeutics is a biopharmaceutical company developing therapies targeting cancers that express abnormal carbohydrates/glycans. These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric, and breast, and are exploited by tumor cells to suppress innate immune function, enable tissue invasion and metastasis, resist chemotherapy, and promote a stem-cell phenotype. Therefore, therapeutic antibodies targeting TACAs have the potential to not only kill cancer cells but also re-engage the immune system and overcome chemo-resistance.
CEO: Jeff Behrens
12 articles with Siamab Therapeutics
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.
Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer
Siamab Therapeutics, Inc. today announced the publication of positive preclinical data for its ST1 antibody drug conjugate (ADC) in multiple models of ovarian cancer.
Siamab Therapeutics Announces Publication of New Data on its ST1 Lead Program in the Journal Oncotarget
Study Findings Show Treatment with ST1 Antibody Drug Conjugate (ADC) Inhibited Growth of Chemoresistant Ovarian Tumor Cells Expressing STn in vitro and in vivo
Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018
Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase 2018
Siamab Therapeutics announced that Jeff Behrens, president and chief executive officer, will present at the 10th annual Biotech Showcase™ conference in San Francisco on Tuesday, January 9, 2018.
Siamab Therapeutics Presents New Preclinical Safety Data for ST1 Antibody Therapeutics Program at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
These results add to the company’s efficacy data findings showing that its anti-STn antibody therapeutics inhibit tumor progression in cell-line-derived and patient-derived xenograft (PDX) ovarian cancer and pancreatic cancer mouse models, with complete regression observed in some treatment arms.
Siamab And Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration To Develop Antibody Therapeutics Targeting Multiple Solid Tumors
Siamab Presents New Data At AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth In Ovarian Cancer Models
Siamab Presented New Data For Its Anti-Stn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells As A Promising Cancer Immunotherapy Target At Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference
Siamab Presents New Preclinical Data For Its Novel Anti-Stn Antibodies, Antibody-Drug Conjugates, And Anti-Stn Bispecific Antibodies At The AACR Annual Meeting 2017
Siamab To Present New Preclinical Data For Its Novel Antibodies And Antibody Drug Candidates At AACR Annual Meeting 2017
Siamab Announces Publication Of New Preclinical Data In The Journal mAbs Describing Its Novel Monoclonal Antibody Approach To Targeting The Tumor-Associated Carbohydrate Antigen STn